What is AGT103-T?

American Gene Technologies™ developed AGT103-T, a patented lentivirus designed to give CD4 T cells the ability to survive attack by HIV and support effective antiviral immune response. The lentivirus vector modifies HIV-specific CD4 T cells and prevents infection by CCR5- or CXCR4-tropic strains of HIV; reduces depletion of CD4 T cells during exposure to HIV; and prevents a latently-infected cell from releasing new HIV virus particles. By achieving this high dose of HIV-specific CD4 T cells that are protected from attack by HIV, we are hopeful this treatment could potentially reconstitute the immune system and restore an ability to make antiviral immune responses for natural control of HIV.